https://scholars.lib.ntu.edu.tw/handle/123456789/631026
標題: | Dual Antiplatelet Therapy in the Management of Acute Minor Ischemic Stroke and High-Risk Transient Ischemic Attack: An Expert Consensus Statement From Taiwan Stroke Society and Taiwan Society of Emergency Medicine | 作者: | Chen, Po-Lin Chen, Ying-Ju Chung, Chih-Ping Seak, Chen-June JIANN-SHING JENG MING-JU HSIEH Lien, Li-Ming Chen, Jiann-Hwa Chen, Yu-Wei Chiu, Te-Fa Lee, Jiunn-Tay Ng, Chip-Jin |
關鍵字: | acute minor ischemic stroke; consensus statement; dual antiplatelet therapy; transient ischemic attack | 公開日期: | 1-九月-2022 | 出版社: | TAIWAN SOC EMERGENCY MEDICINE | 卷: | 12 | 期: | 3 | 起(迄)頁: | 85 | 來源出版物: | Journal of acute medicine | 摘要: | The aim of this review is to achieve a consensus between Taiwan Stroke Society (TSS) and Taiwan Society of Emergency Medicine (TSEM) to manage acute non-cardioembolic minor ischemic stroke (MIS) and high-risk transient ischemic attack (TIA). The methodology is to review the recent findings from clinical trials of dual antiplatelet therapy (DAPT) from 2010 to 2021 and updates in clinical practice guidelines from 2018 to 2022 for non-cardioembolic MIS/TIA management at the acute stage. Four leading clinical studies, CHANCE, POINT, THALES, and CHANCE-2 along with other relevant studies introducing DAPT, are discussed in this review. The risk-benefit profile between stroke recurrence reduction and major bleeding increase is also elucidated. TSS and TSEM concluded that for patients presenting with non-cardioembolic MIS or high-risk TIA who did not receive intravenous alteplase, initiation of DAPT within 24 hours after stroke onset and continued up to 21 days, followed by antiplatelet monotherapy, is effective in reducing recurrent ischemic stroke for a period of up to 90 days. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/631026 | ISSN: | 2211-5587 | DOI: | 10.6705/j.jacme.202209_12(3).0001 |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。